FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280493602> ?p ?o ?g. }

• W4280493602 endingPage "1027" @default.
• W4280493602 startingPage "1019" @default.
• W4280493602 abstract "The purpose of the study was to perform a post hoc analysis to explore the effect of baseline anatomic characteristics identified on OCT on best-corrected visual acuity (BCVA) responses to risuteganib from the completed phase II study in subjects with dry age-related macular degeneration (AMD).Post hoc analysis of a randomized, double-masked, placebo-controlled, phase II study.Eyes with intermediate dry AMD with BCVA between 20/40 and 20/200. Patients with concurrent vision-influencing or macula-obscuring ocular pathologies were excluded.Patients were randomized to receive a 1-mg intravitreal risuteganib injection or a sham injection at baseline. A second 1-mg intravitreal injection of risuteganib was given at week 16 to those in the treatment arm. Two independent, masked reading centers evaluated the baseline anatomic characteristics on OCT to explore features associated with positive responses to risuteganib.Treatment response was defined as a gain of ≥ 8 letters in BCVA from baseline to week 28 in the treatment arm, compared with baseline to week 12 in the sham group. Anatomic parameters, measured by retinal segmentation platforms, including measures of retinal thickness were compared between the responders and nonresponders to risuteganib.Thirty-nine patients completed the study and underwent analysis. In the treatment arm, 48% of eyes demonstrated treatment responses, compared with 7% in the sham group. In the quantitative anatomic assessment, enhanced ellipsoid integrity, greater outer retinal thickness, and decreased geographic atrophy were associated with increased BCVA gains to risuteganib.This post hoc analysis demonstrated that baseline OCT features may help determine the likelihood of a functional response to risuteganib. The characterization of higher-order OCT features may provide important information regarding biomarkers for treatment response and could facilitate optimized clinical trial enrollment and enrichment." @default.
• W4280493602 created "2022-05-22" @default.
• W4280493602 creator A5009809226 @default.
• W4280493602 creator A5019125791 @default.
• W4280493602 creator A5034626761 @default.
• W4280493602 creator A5060670617 @default.
• W4280493602 creator A5066264108 @default.
• W4280493602 creator A5072863451 @default.
• W4280493602 creator A5073193063 @default.
• W4280493602 creator A5082501044 @default.
• W4280493602 creator A5090549318 @default.
• W4280493602 creator A5090864408 @default.
• W4280493602 date "2022-11-01" @default.
• W4280493602 modified "2023-10-06" @default.
• W4280493602 title "Impact of Baseline Quantitative OCT Features on Response to Risuteganib for the Treatment of Dry Age-Related Macular Degeneration" @default.
• W4280493602 cites W1979854281 @default.
• W4280493602 cites W2060040689 @default.
• W4280493602 cites W2079413294 @default.
• W4280493602 cites W2160226180 @default.
• W4280493602 cites W2263018236 @default.
• W4280493602 cites W2270960613 @default.
• W4280493602 cites W2291910723 @default.
• W4280493602 cites W2316419639 @default.
• W4280493602 cites W2333998038 @default.
• W4280493602 cites W2346360310 @default.
• W4280493602 cites W2602573314 @default.
• W4280493602 cites W2613186415 @default.
• W4280493602 cites W2626143223 @default.
• W4280493602 cites W2735396028 @default.
• W4280493602 cites W2772059204 @default.
• W4280493602 cites W2800349779 @default.
• W4280493602 cites W2803921547 @default.
• W4280493602 cites W2913311753 @default.
• W4280493602 cites W2914138564 @default.
• W4280493602 cites W2944120685 @default.
• W4280493602 cites W2947329651 @default.
• W4280493602 cites W2954675396 @default.
• W4280493602 cites W2985770405 @default.
• W4280493602 cites W2997639937 @default.
• W4280493602 cites W3022251751 @default.
• W4280493602 cites W3022543352 @default.
• W4280493602 cites W3080312472 @default.
• W4280493602 cites W3083259832 @default.
• W4280493602 cites W3085783162 @default.
• W4280493602 cites W3093406755 @default.
• W4280493602 cites W3108271609 @default.
• W4280493602 cites W3108292935 @default.
• W4280493602 cites W3135623921 @default.
• W4280493602 cites W3138156139 @default.
• W4280493602 cites W3145314436 @default.
• W4280493602 cites W3176943255 @default.
• W4280493602 cites W4206365209 @default.
• W4280493602 doi "https://doi.org/10.1016/j.oret.2022.05.002" @default.
• W4280493602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35569763" @default.
• W4280493602 hasPublicationYear "2022" @default.
• W4280493602 type Work @default.
• W4280493602 citedByCount "4" @default.
• W4280493602 countsByYear W42804936022023 @default.
• W4280493602 crossrefType "journal-article" @default.
• W4280493602 hasAuthorship W4280493602A5009809226 @default.
• W4280493602 hasAuthorship W4280493602A5019125791 @default.
• W4280493602 hasAuthorship W4280493602A5034626761 @default.
• W4280493602 hasAuthorship W4280493602A5060670617 @default.
• W4280493602 hasAuthorship W4280493602A5066264108 @default.
• W4280493602 hasAuthorship W4280493602A5072863451 @default.
• W4280493602 hasAuthorship W4280493602A5073193063 @default.
• W4280493602 hasAuthorship W4280493602A5082501044 @default.
• W4280493602 hasAuthorship W4280493602A5090549318 @default.
• W4280493602 hasAuthorship W4280493602A5090864408 @default.
• W4280493602 hasConcept C118487528 @default.
• W4280493602 hasConcept C126322002 @default.
• W4280493602 hasConcept C141071460 @default.
• W4280493602 hasConcept C142724271 @default.
• W4280493602 hasConcept C168563851 @default.
• W4280493602 hasConcept C204787440 @default.
• W4280493602 hasConcept C27081682 @default.
• W4280493602 hasConcept C2776403814 @default.
• W4280493602 hasConcept C2778257484 @default.
• W4280493602 hasConcept C2780827179 @default.
• W4280493602 hasConcept C2781172350 @default.
• W4280493602 hasConcept C2991880128 @default.
• W4280493602 hasConcept C2992886853 @default.
• W4280493602 hasConcept C67761136 @default.
• W4280493602 hasConcept C71924100 @default.
• W4280493602 hasConceptScore W4280493602C118487528 @default.
• W4280493602 hasConceptScore W4280493602C126322002 @default.
• W4280493602 hasConceptScore W4280493602C141071460 @default.
• W4280493602 hasConceptScore W4280493602C142724271 @default.
• W4280493602 hasConceptScore W4280493602C168563851 @default.
• W4280493602 hasConceptScore W4280493602C204787440 @default.
• W4280493602 hasConceptScore W4280493602C27081682 @default.
• W4280493602 hasConceptScore W4280493602C2776403814 @default.
• W4280493602 hasConceptScore W4280493602C2778257484 @default.
• W4280493602 hasConceptScore W4280493602C2780827179 @default.
• W4280493602 hasConceptScore W4280493602C2781172350 @default.
• W4280493602 hasConceptScore W4280493602C2991880128 @default.
• W4280493602 hasConceptScore W4280493602C2992886853 @default.
• W4280493602 hasConceptScore W4280493602C67761136 @default.

• next